September 09, 2022
Back Page
42
9
A prime opportunity for pharma to raise its strategic game in ESG.
September 09, 2022
Features
42
9
Our latest metrics tally across seven business-key measures uncovers some familiar players pacing the field in delivering shareholder value and getting the most from their investments.
September 09, 2022
Executive Roundtable
42
9
Senior leaders in pharma, healthcare marketing and communications, and advertising got together to discuss the progress and lingering roadblocks in advancing diversity, equity, and inclusion strategies in the life sciences—where the common thread seems clear: the messenger matters.
September 09, 2022
Features
42
9
FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.
September 09, 2022
Features
42
9
A fresh look at how industry benchmarks can help fortify new drug launches to overcome today’s new market-entry barriers and higher expectations.
September 09, 2022
Features
42
9
Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.
September 09, 2022
Features
42
9
Launch of novel drug for rare neuromuscular disorder seeks to give voice to the patients.
September 09, 2022
Features
42
9
Use against pair of pathways could pave way for standout in stocked eye disease market.
September 09, 2022
Features
42
9
Tapping the potential of new market mindset in insomnia—delivering a quality next day.
September 09, 2022
Features
42
9
Dual-targeted injection poised to rock GLP-1 field in diabetes—and eventually weight loss.
September 09, 2022
Features
42
9
More favorable administration, reimbursement could separate latest PCSK9 entrant.
September 09, 2022
Features
42
9
Spotlighting the stories of five noteworthy biopharma brand launches—and the diverse disorders they address with novel approaches in science and market access.
September 09, 2022
Executive Profile
42
9
Pharm Exec catches up with longtime Merck international business leader Kevin Ali to find out how Organon, the ambitious Merck spinoff he formed just over a year ago, has fared so far in delivering on its mission of creating a global leader and difference-maker in women’s health.
September 09, 2022
Finance
42
9
Biotech stocks and the indexes have staged an impressive recovery.
September 09, 2022
Marketing
42
9
What the rising rate of physician-hospital affiliations means for pharma.
September 09, 2022
Leadership
42
9
How companies can adapt to today’s fast-changing hiring climate.
September 09, 2022
Europe Report
42
9
And, in equal measure, patients and doctors—as EU mulls new rules.
September 09, 2022
From the Editor
42
9
Pharm Exec releases its annual product launch feature articles.
September 09, 2022
Issue PDF
42
9
Click the title above for a link to open the Pharmaceutical Executive September 2022 issue in an interactive PDF format.
August 15, 2022
Washington Report
42
9
Pharma loses battle to block price negotiations, but implementation faces many challenges.